The event served as an extended portfolio activity of the Cell and Gene Therapy (CGT) Pathfinder Challenge Portfolio, led by Dr. Iordanis Arzimanoglou, EIC Programme Manager for Health and Biotech. Representatives from companies or projects funded by the European Innovation Council (EIC) at the Transition or Accelerator levels were also active participants in the symposium.
The event was as an excellent platform to present the CGT Pathfinder portfolio and explain its structure, demonstrate the effectiveness of EIC pro-active portfolio-management through a panel discussion with EIC CGT projects, and build bridges between the different actors involved in the CGT community. The symposium was the final activity of the EIC CGT campaign month, which aimed to boost the visibility of the CGT portfolio through several activities, such as the EIC podcast ''Fighting cancer with Cell and Gene therapy''.
The symposium featured three leading scientists/physicians in the CGT field as keynote speakers: Prof. Hans-Peter Kiem, Dr. Michael Wenger, Prof. Seppo Ylä-Herttuala. Over 100 participants from industry, public sector, and research institutions attended the event, making it a remarkable session among the overall Congress. High level policy makers also joined the Symposium.
Recently, the strategic plan for CGT portfolio managed by the EIC Programme Manager Iordanis Arzimanoglou was published. It describes the coordinated action at portfolio, rather than individual project level, in order to capture opportunities and tackle challenges in technology, regulation, and exploitation in the CGT field.
Recording from the Symposium:
Documents presented at the Symposium:
EIC Cell & Gene Therapy Community
EIC Accelerator
- CD20CARNAPT - iTANK: a nuniversal technology to boost the efficacy of CAR T cell therapies by inducing dual mode-of-action - The critical shift to single-cell formats in functional analyses of living cells
- CELLULARITY - The critical shift to single-cell formats in functional analyses of living cells
- EuroXpand - European clinical validation of a new ex vivo expanded stem cell therapy for cardiac regeneration after acute myocardial infarction
- FIGHT-DM1 - First In class oliGo THerapy for Myotonic Dystrophy type 1 (DM1)
- I-CREATE - Fighting cancer with next generation oncolytic immunotherapy in ovarian, head & neck, and lung cancers (Immune Checkpoint Response Enabling Adenovirus Technology )
- LAKHESYS - Building the machine to make the medicines of tomorrow
- Smart ProTcell - Smart Immune ProTcell: first-in-class allogeneic thymus empowered T cell therapy platform for fast and durable immune system reconstitution
- TREG - Innovative cell therapy targeting Diabetes Type 1
EIC Accelerator
- FIBREX - Targeting cardiac fibrosis with next generation RNA therapeutics
- TAONas-LUAD - Therapeutic Antisense Oligonucleotides Targeting NUMB Alternative Splicing in Lung Adenocarcinoma
- MACOV - Macrophage-based immunotherapy of platinum-resistant ovarian cancer
- TRACTION - Translational Control of Transcription Factor Gene Therapy
- CARxALL - Next generation, off-the-shelf CD1a/CCR9-directed CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia
- TraffikGene-Tx - TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery
EIC Pathfinder
- AiPSC - AI-powered platform for autologous iPSC manufacturing
- X-PAND - Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical application
- MUTAVAC - Targeting cancer with mutanome based stem cell vaccine
- SMARTER - Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process control
- PAT4CGT - Automated online monitoring & control to improve processes and decision making in cell and gene therapy manufacturing
- T-FITNESS - Fine-Tuning T CELL Networks OF Exhaustion by Synthetic Sensors
- EdiGenT - New Prime Editing and non-viral delivery strategies for Gene Therapy
- AAVOLUTION - Next-generation AAV vectors for liver-directed gene therapy
- NOVISTEM - Non-Viral gene modified STEM cell therapy
- INCITE - Immune Niches for Cancer ImmunoTherapy Enhancement
- ULISES - Immunological incompatibility as a basis for cancer curing and vaccination
- I-GENE - In-vivo Gene Editing by Nanotransducers
- iAds - Intelligent design of adenovirus vectors (iAds)
- NANO-ENGINE - A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system
- HyperTargIPS-NK - Hyper-targeting CAR NK cells from induced pluripotent stem cells for novel off-the-shelf anti-tumor therapies
- CAR T-REX - CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment
Details
- Publication date
- 30 November 2023